Certainly other chemokine/receptor interactions can also contribute to immunotherapy response in pancreatic cancer, as evident from recent CCR2 and CCR5 inhibitors, which may be of interest for future study (46). The gene discussed is CCR2; the disease is familial pancreatic carcinoma.